Cathay International Holdings Ld Lansen appoints Executive Director & Group CEO
09 February 2018 - 6:43PM
RNS Non-Regulatory
TIDMCTI
Cathay International Holdings Ld
09 February 2018
Final version via RNS Reach
Cathay International Holdings Limited
("Cathay" or the "Company")
Cathay's subsidiary Lansen
Change of executive director, member of executive committee
and
group chief executive officer
Hong Kong, 9 February 2018 - Cathay International Holdings Ltd.
(LSE: CTI.L), an operator and investor in the growing healthcare
sector in the People's Republic of China (the "PRC"), announces
that Lansen Pharmaceutical Holdings Ltd ("Lansen") (HKEX: 503), the
Company's 50.56% owned subsidiary, has announced today that Mr.
Chen Li ("Mr. Chen") will be appointed as the Executive Managing
Director of Lansen, a member of the Executive Committee and the
Chief Executive Officer of the Lansen group with effect from 1
March 2018.
Mr. Chen Li, age 56, has over 25 years of experience in the
pharmaceutical industry. Prior to joining the Lansen group, Mr.
Chen has been General Manager in Alfa Wassermann China since July
2014. Mr. Chen worked for a number of internationally renowned
pharmaceutical companies in the past. He was previously General
Manager of China in Abbot from June 2009 to November 2012 and
Assistant Vice President in Wyeth Pharmaceuticals Shanghai from
2004 to June 2009. During the period from 1992 to 2004, Mr. Chen
also worked in GlaxoSmithKline, Hoechst China, Bayer China, BASF
Knoll China and Roussel China. Mr. Chen obtained a bachelor!--s
degree in Medicine (Internal Medicine Doctor) from Tongji Medical
University in 1983.
The full text of the Lansen Announcement can be found at the
Announcements & Notices section of Lansen's homepage at
http://holding.lansen.com.cn/en/newslist.aspx?NodeCode=10002000700050005.
-ENDS-
For further enquiries, please contact:
Cathay International Holdings
Limited Tel: +852 2828
Eric Siu (Finance Director) 9289
Patrick Sung (Director and
Controller)
Consilium Strategic Communications
Mary-Jane Elliott / Matthew Tel: +44 (0) 203
Neal / Lindsey Neville 709 5700
About Cathay
Cathay International Holdings Limited (LSE: CTI.L) is a main
market listed investment holding company and an operator and
investor in the growing healthcare sector in the People's Republic
of China (the "PRC"). The Company and its subsidiaries
(collectively the "Group") aim to leverage on growth opportunities
in the strong and growing domes c demand for high quality
healthcare products in the PRC and build its portfolio companies
into market sector leaders with competitive edge. Cathay has
already demonstrated a strong track record of identifying high
growth potential investment opportunities in this area including:
Lansen, a leading specialty pharmaceutical company focused on
rheumatology and dermatology in the PRC; Haizi, a company engaged
in the manufacture, marketing and sale of inositol and its
by-product, di-calcium phosphate; Natural Dailyhealth, a company
engaged in production and sales of plant extracts for use as key
active ingredients in healthcare products; and Botai, a company
engaged in collagen products.
The Group employs approximately 2,000 people across the PRC,
including over 30 specialist corporate and business development
staff based at the holding company's offices in Hong Kong and
Shenzhen. Cathay also has a hotel investment. For more information
please visit the Company's website:
http://www.cathay-intl.com.hk.
About Lansen
Lansen, whose shares are listed on the mainboard of the Hong
Kong Stock Exchange, is a 50.56% owned subsidiary of Cathay. Lansen
is engaged in the manufacture, distribution and development of
specialty prescription drugs for treatment of autoimmune disorder
in rheumatology and dermatology. Lansen is in the leading market
position in disease modifying anti-rheumatic drugs ("DMARDs") for
treatment of rheumatoid arthritis ("RA") in the PRC. Lansen has
established an extensive distribution network, covering more than
1,000 hospitals in four municipalities, 25 provinces and cities in
the PRC. For more information please visit the Lansen's website:
http://www.lansen.com.cn/en/index.aspx.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRASSASWUFASEDE
(END) Dow Jones Newswires
February 09, 2018 02:43 ET (07:43 GMT)
Cathay International Hol... (LSE:CTI)
Historical Stock Chart
From Apr 2024 to May 2024
Cathay International Hol... (LSE:CTI)
Historical Stock Chart
From May 2023 to May 2024